PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses. PJT operates businesses across strategic advisory, strategic capital markets, restructuring, shareholder advisory and capital raising. The firm has advised on over $1 trillion in M&A transactions including AbbVie's $63 billion acquisition of Allergan, T-Mobile's $59 billion merger with Sprint, and Mylan's $50 billion merger with Pfizer subsidiary, Upjohn.
| trading_symbol | registrant_name | time | price | change | percentage_change | 
|---|---|---|---|---|---|
| PJT | PJT Partners Inc. | 2025-10-30 16:30:05 | 169.18 | 0 | 0 | 
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PJT | 0001626115 | PJT Partners Inc. | US69343T1079 | 549300W3WBEQUBKYTN87 | 364797143 | NYSE | 6282 | Investment Advice | 1231 | DE | 280 PARK AVENUE | NEW YORK | NY | 10017 | UNITED STATES | US | 212-364-7800 | 280 PARK AVENUE, NEW YORK, NY, 10017 | 280 PARK AVENUE, NEW YORK, NY, 10017 | — | Investment banking | 2015 | — | 1,143 | http://pjtpartners.com/ | 2,500,000,000 | — | 24,800,541 | PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses. PJT operates businesses across strategic advisory, strategic capital markets, restructuring, shareholder advisory and capital raising. The firm has advised on over $1 trillion in M&A transactions including AbbVie's $63 billion acquisition of Allergan, T-Mobile's $59 billion merger with Sprint, and Mylan's $50 billion merger with Pfizer subsidiary, Upjohn. | 2025-10-30 13:09:34 | 
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding | 
|---|---|---|---|---|---|---|
| 2024 | 2,500,000,000 | 900,000,000 | 56.25 | — | — | — | 
| 2023 | 1,600,000,000 | -100,000,000 | -5.8824 | — | — | — | 
| 2022 | 1,700,000,000 | 0 | 0 | — | — | — | 
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation | 
|---|---|---|---|---|---|---|---|---|
| David A. Travin | General Counsel | 2024 | 500,000 | 1,309,600 | 1,178,400 | — | — | 2,988,000 | 
| Helen T. Meates | Chief Financial Officer | 2024 | 1,000,000 | 1,847,700 | 1,640,300 | — | — | 4,488,000 | 
| Paul J. Taubman | CEO, Chairman | 2024 | 1,000,000 | 0 | 0 | — | — | 1,000,000 | 
| Paul J. Taubman | CEO, Chairman | 2023 | 1,000,000 | 0 | 0 | — | — | 1,000,000 | 
| David A. Travin | General Counsel | 2023 | 500,000 | 1,071,500 | 666,500 | — | — | 2,238,000 | 
| Fiscal Year | Employee Count | 
|---|---|
| 2024 | 1,143 | 
| 2023 | 1,012 | 
| 2022 | 907 | 
| Fiscal Year | 2024 | 2023 | 2022 | 
|---|---|---|---|
| Revenue | 1,493,177,000 | 1,153,182,000 | 1,025,505,000 | 
| Cost Of Revenue | — | — | — | 
| Gross Profit | — | — | — | 
| Research And Development Expenses | — | — | — | 
| General And Administrative Expenses | — | — | — | 
| Operating Expenses | 1,222,608,000 | 975,573,000 | 824,034,000 | 
| Operating Income | — | — | — | 
| Net Income | 134,393,000 | 81,799,000 | 90,534,000 | 
| Earnings Per Share Basic | 5.28 | 3.24 | 3.61 | 
| Earnings Per Share Diluted | 4.92 | 3.12 | 3.51 | 
| Weighted Average Shares Outstanding Basic | 25,454,445 | 25,255,327 | 25,077,835 | 
| Weighted Average Shares Outstanding Diluted | 44,105,131 | 41,882,034 | 26,616,640 | 
| Fiscal Year | 2024 | 2023 | 2022 | 
|---|---|---|---|
| Cash And Cash Equivalents | 483,877,000 | 355,543,000 | 173,235,000 | 
| Marketable Securities Current | — | — | — | 
| Accounts Receivable | 320,783,000 | 263,529,000 | 317,751,000 | 
| Inventories | — | — | — | 
| Non Trade Receivables | — | — | — | 
| Other Assets Current | — | — | — | 
| Total Assets Current | — | — | — | 
| Marketable Securities Non Current | — | — | — | 
| Property Plant And Equipment | 22,137,000 | 25,901,000 | 30,693,000 | 
| Other Assets Non Current | — | — | — | 
| Total Assets Non Current | — | — | — | 
| Total Assets | 1,635,334,000 | 1,434,978,000 | 1,050,652,000 | 
| Accounts Payable | — | — | — | 
| Deferred Revenue | — | — | — | 
| Short Term Debt | — | — | — | 
| Other Liabilities Current | — | — | — | 
| Total Liabilities Current | — | — | — | 
| Long Term Debt | — | — | — | 
| Other Liabilities Non Current | — | — | — | 
| Total Liabilities Non Current | — | — | — | 
| Total Liabilities | 733,691,000 | 573,814,000 | 291,094,000 | 
| Common Stock | 340,000 | 324,000 | 310,000 | 
| Retained Earnings | 228,594,000 | 118,332,000 | 60,969,000 | 
| Accumulated Other Comprehensive Income | -1,661,000 | -467,000 | -2,274,000 | 
| Total Shareholders Equity | 187,013,000 | 244,669,000 | 185,106,000 | 
| Fiscal Year | 2024 | 2023 | 2022 | 
|---|---|---|---|
| Depreciation And Amortization | 12,799,000 | 14,047,000 | 15,475,000 | 
| Share Based Compensation Expense | 209,185,000 | 178,535,000 | 165,528,000 | 
| Other Non Cash Income Expense | 1,888,000 | 935,000 | -2,793,000 | 
| Change In Accounts Receivable | 55,920,000 | -51,904,000 | 32,497,000 | 
| Change In Inventories | — | — | — | 
| Change In Non Trade Receivables | — | — | — | 
| Change In Other Assets | -11,031,000 | 33,515,000 | 42,659,000 | 
| Change In Accounts Payable | — | — | — | 
| Change In Other Liabilities | — | — | — | 
| Cash From Operating Activities | 530,950,000 | 441,534,000 | 242,731,000 | 
| Purchases Of Marketable Securities | 369,988,000 | 328,767,000 | 143,929,000 | 
| Sales Of Marketable Securities | 392,074,000 | 298,348,000 | 94,128,000 | 
| Acquisition Of Property Plant And Equipment | 3,298,000 | 3,927,000 | 3,434,000 | 
| Acquisition Of Business | 10,727,000 | — | — | 
| Other Investing Activities | — | — | — | 
| Cash From Investing Activities | 8,061,000 | -34,346,000 | -53,235,000 | 
| Tax Withholding For Share Based Compensation | 37,477,000 | 19,406,000 | 17,792,000 | 
| Payments Of Dividends | 24,131,000 | 24,436,000 | 24,632,000 | 
| Issuance Of Common Stock | — | — | — | 
| Repurchase Of Common Stock | 235,104,000 | 116,738,000 | 109,484,000 | 
| Issuance Of Long Term Debt | — | — | — | 
| Repayment Of Long Term Debt | 0 | 15,000,000 | 42,000,000 | 
| Other Financing Activities | — | — | — | 
| Cash From Financing Activities | -408,684,000 | -228,077,000 | -210,021,000 | 
| Change In Cash | 128,334,000 | 182,308,000 | -27,246,000 | 
| Cash At End Of Period | 483,877,000 | 355,543,000 | 173,235,000 | 
| Income Taxes Paid | 36,082,000 | 23,288,000 | 28,578,000 | 
| Interest Paid | 0 | 20,000 | 133,000 | 
| Fiscal Year | 2024 | 2023 | 2022 | 
|---|---|---|---|
| Earnings Per Share | 5.28 | 3.24 | 3.61 | 
| Price To Earnings Ratio | 29.8883 | 31.4414 | 20.4127 | 
| Earnings Growth Rate | 62.963 | -10.2493 | -15.0588 | 
| Price Earnings To Growth Ratio | 0.4747 | -3.0677 | -1.3555 | 
| Book Value Per Share | 35.4218 | 34.0983 | 30.288 | 
| Price To Book Ratio | 4.4552 | 2.9875 | 2.433 | 
| Ebitda | 183,274,000 | 119,134,000 | 134,587,000 | 
| Enterprise Value | — | — | — | 
| Dividend Yield | 0.006 | 0.0095 | 0.0133 | 
| Dividend Payout Ratio | 0.1796 | 0.2987 | 0.2721 | 
| Debt To Equity Ratio | — | — | — | 
| Capital Expenditures | 9,035,000 | 9,255,000 | 9,021,000 | 
| Free Cash Flow | 521,915,000 | 432,279,000 | 233,710,000 | 
| Return On Equity | 0.7186 | 0.3343 | 0.4891 | 
| One Year Beta | 1.2671 | 0.6868 | 0.694 | 
| Three Year Beta | 0.7891 | 0.7647 | 1.0186 | 
| Five Year Beta | 1.0088 | 0.9991 | 1.0343 | 
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction | 
|---|---|---|---|---|---|
| Rafferty Emily K | Director | 2025-09-17 | 9 | A | 6,674 | 
| Costos James | Director | 2025-09-17 | 14 | A | 10,386 | 
| CURRIE PETER L S | Director | 2025-09-17 | 2 | A | 1,737 | 
| RYAN THOMAS M | Director | 2025-09-17 | 17 | A | 12,831 | 
| Travin David Adam | General Counsel | 2025-09-17 | 16 | A | 12,405 | 
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security | 
|---|---|---|---|---|
| Gibbs Wealth Management | 2025-09-30 | 902,534 | 5,078 | 177.7341 | 
| TEACHER RETIREMENT SYSTEM OF TEXAS | 2025-09-30 | 2,718,912 | 15,298 | 177.7299 | 
| Millstone Evans Group, LLC | 2025-09-30 | 1,955 | 11 | 177.7273 | 
| Parkside Financial Bank & Trust | 2025-09-30 | 3,378 | 19 | 177.7895 | 
| STRS OHIO | 2025-09-30 | 1,226,337 | 6,900 | 177.73 | 
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets | 
|---|---|---|---|---|---|---|
| SHELTON FUNDS | 2025-08-31 | K Shares | SMLKX | 866 | 155,014 | 0.2998 | 
| SHELTON FUNDS | 2025-08-31 | Investor Shares | SMCIX | 866 | 155,014 | 0.2998 | 
| Tidal Trust III | 2025-08-31 | VistaShares Target 15 USA Quality Income ETF | QUSA | 359 | 64,261 | 0.3699 | 
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT SMALL CAP FUND - CLASS A | SLPAX | 1,020 | 182,580 | 0.0963 | 
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Extended Market Index Fund - Class A | SMXAX | 3,400 | 608,600 | 0.0502 |